References
  1. Schüller, H., Klein, F., Lübbert, M. et al. Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report. Ann Hematol (2020). https://doi.org/10.1007/s00277-020-04318-6
  2. Risitano, A., Maciejewski, J., Muranski, P. et al. Large granular lymphocyte (LGL)-like clonal expansions in paroxysmal nocturnal hemoglobinuria (PNH) patients. Leukemia 19,217–222 (2005). https://doi.org/10.1038/sj.leu.2403617
  3. Jia Yu, Xuan Yuan, Hang Chen, Shruti Chaturvedi, Evan M. Braunstein, Robert A. Brodsky; Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood 2020; 136 (18): 2080–2089. doi: https://doi.org/10.1182/blood.2020008248
  4. Hrishikesh S. Kulkarni, John P. Atkinson; Targeting complement activation in COVID-19. Blood 2020; 136 (18): 2000–2001. doi: https://doi.org/10.1182/blood.2020008925
  5. Risitano AM. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies. Adv Exp Med Biol. 2013;735:155-72. doi: 10.1007/978-1-4614-4118-2_10. PMID: 23402025.